BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 25956686)

  • 1. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.
    Firor AE; Jares A; Ma Y
    Exp Biol Med (Maywood); 2015 Aug; 240(8):1087-98. PubMed ID: 25956686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T Cell Therapy: A Game Changer in Cancer Treatment.
    Almåsbak H; Aarvak T; Vemuri MC
    J Immunol Res; 2016; 2016():5474602. PubMed ID: 27298832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
    Maus MV; Levine BL
    Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CAR T-cell therapy: Balance of efficacy and safety].
    Kulemzin SV; Kuznetsova VV; Mamonkin M; Taranin AV; Gorchakov AA
    Mol Biol (Mosk); 2017; 51(2):274-287. PubMed ID: 28537234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
    Gill S; June CH
    Immunol Rev; 2015 Jan; 263(1):68-89. PubMed ID: 25510272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
    Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
    Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor T-cell therapy to target hematologic malignancies.
    Kenderian SS; Ruella M; Gill S; Kalos M
    Cancer Res; 2014 Nov; 74(22):6383-9. PubMed ID: 25371415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
    Liu L; Sun M; Wang Z
    Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
    Nagle SJ; Garfall AL; Stadtmauer EA
    Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date.
    Davila ML; Sauter C; Brentjens R
    Cancer J; 2015; 21(6):470-4. PubMed ID: 26588678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].
    Xu XJ; Zhao HZ; Tang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):521-5. PubMed ID: 23628068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.